An already big immunology market is only getting bigger: analyst by Angus Liu Thursday, April 4, 2019 Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
FTC zeroes in on potential BMS, Celgene psoriasis overlap by Carly Helfand Tuesday, March 26, 2019 Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger.
Celgene guns for expanded Otezla label in scalp psoriasis by Arlene Weintraub Tuesday, October 9, 2018 Expanding Otezla's market to scalp psoriasis could be challenging for Celgene, in light of hurdles such as mounting competition.
Despite Merck and J&J reports, net prices probably aren't down by Eric Sagonowsky Tuesday, April 10, 2018 Merck and J&J presented numbers suggesting pharma faces increased pricing pressure, but one analyst is skeptical.
Celgene COO Smith exits suddenly in wake of MS miss by Arlene Weintraub Tuesday, April 3, 2018 The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.
On the heels of its Juno buy, Celgene posts double-digit growth by Eric Sagonowsky Thursday, January 25, 2018 Despite struggles in 2017, Celgene turned in 16% annual sales growth, buoyed by key drugs Revlimid, Pomalyst and Otezla.
To cope with pricing vise, lean on cancer, not inhalers by Eric Sagonowsky Tuesday, January 16, 2018 Good news for pharma's pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, a new analysis shows.
Celgene expects growth as it puts setbacks behind it by Eric Sagonowsky Monday, January 8, 2018 SAN FRANCISCO—Looking to recover from a tough year, Celgene rolled out its 2018 guidance at the J.P. Morgan Healthcare conference in San Francisco.
Celgene wipes $1B to $2B off its 2020 guidance by Eric Sagonowsky Thursday, October 26, 2017 Celgene on Thursday reported third-quarter financial results that further spooked investors.
Celgene on track for $21B-plus by 2020 by Eric Sagonowsky Tuesday, January 10, 2017 Celgene on Monday reported a 2016 EPS beat and rolled out its guidance for 2017.
